Current Edition

Drug Development in Systemic Lupus Erythematosus – Can it be Successful?

Systemic lupus erythematosus (SLE) is an autoimmune disease
that causes the immune system to produce several types of
antibodies, particularly against cell nuclei. This disease is
extremely heterogeneous in how it manifests, which leads to
significant problems and delays in diagnosis. SLE is probably
one of the most challenging indications for drug development.
Without understanding its challenges, as well as ways of
addressing them, it is very hard to execute a successful trial,
even with a drug that may be successful. Marcin Ernst, MD,
Vice President, Clinical Development at INC Research,
explains how the lessons learned from past challenges will
allow sponsors to successfully bring new therapies to the